



JUN 17 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

#7

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/008,982
Filing Date	12/06/2001
First Named Inventor	KUO, et al
Group Art Unit	1614 1624
Examiner Name	COLEMAN
Attorney Docket Number	ORT-1551

U.S. PATENT DOCUMENTS

RECEIVED
JUN 24 2002
1600/2000
TECH CENTER

FOREIGN PATENT DOCUMENTS

Examiner Signature	Brenda · Coleman	Date Considered	Sept. 29, 2003
-----------------------	------------------	--------------------	----------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. **2** See attached Kinds of U.S. Patent Documents. **3** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **4** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **5** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. **6** Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



#8

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-001

Approved for use through 10/31/2002 OMB 0031-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitution for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Application Number	10/008,982	MAY	1	RECEIVE
Filing Date	12/06/2001			
First Named Inventor	KUO, et. al.	JUN	2	
Group Art Unit	1614-1601	JUL	8	
Examiner Name	COLEMAN	AUG	1600/	
Attorney Docket Number	ORT-1551	SEP	2002	

RECEIVED

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003
-----------------------	----------------	--------------------	----------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-02)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Application Number	10/008,982
Filing Date	12/06/2001
First Named Inventor	KUO, et al.
Group Art Unit	1614 1624
Examiner Name	COLEMAN
Attorney Docket Number	ORT-1551

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BC	1	AHMAD, S., et al., "Expression of the Antisense cDNA for Protein Kinase Cα Attenuates Resistance in Doxorubicin-Resistant MCF-7 Breast Carcinoma Cells," <i>Molecular Pharmacology</i> , 1993, 43:858-862	
BC	2	AKINAGAKA, S., et al., "Antitumor Activity of UCN-01, a Selective Inhibitor of Protein Kinase C, in Murine and Human Tumor Models," <i>Cancer Res.</i> , 1991, 51: 4888-4892	
BC	3	BASTYR III, E. J. and LU, J., "Increased Platelet Protein Kinase C-β(PKC-β) in IDDM," <i>Diabetes</i> , 1993, 42, (Suppl. 1) 97A	
BC	4	BEGEMANN, M., et al., "Treatment of Human Glioblastoma Cells with the Staurosporine Derivative CGP 41251 Inhibits CDC2 and CDK2 Kinase Activity and Increases Radiation Sensitivity," <i>Anticancer Res. (Greece)</i> , 1998, 4A, 18:2275-2282	
BC	5	BELDHUIS, H.J.A., et al., "Long-Term Increase in protein Kinase C-γ and Muscarinic acetylcholine Receptor expression in the Cerebral Cortex of Amygdala-Kindled Rats-A Quantitative Immunocytochemical Study," <i>Neuroscience</i> , 1993, 55:965-73	
BC	6	BENDER, S. L. and GAUTHIER, D. R., "an Approach to Pancratistatin from myo-Inositol", <i>Tetrahedron Lett.</i> , 1996, 37:13-16	
BC	7	BERGER, J., and HAYES, N. S., "A High-Capacity Assay for Activators of Glucose Incorporation into Glycogen in L6 Muscle Cells," <i>Anal. Biochem.</i> , 1998, 261: 159-163	
BC	8	BILDER, G. E., et al., "Phorbol-12, 13-Dibutyrate-Induced Vasoconstriction in Vivo: Characterization of Response in Genetic Hypertension," <i>J. Pharmacol. Exp. Ther.</i> , 1990, 252:526-530	
BC	9	BOLLAG, W. B., et al., "Effects of the selective Protein Kinase C Inhibitor, Ro 31-7549, on the Proliferation of cultured Mouse Epidermal Keratinocytes," <i>J. Invest. Dermatol.</i> , 1993, 100:240-246	
BC	10	CHEN, Y. H., et al., "Sequence of the Human Glycogen-Associated Regulatory Subunit of Type 1 Protein Phosphatase and Analysis of Its Coding Region and mRNA Level in Muscle From Patients With NIDDM," <i>Diabetes</i> , 1994, 43:1234-1241	
BC	11	CHEN, K. S., et al., "Diacylglycerol-Protein Kinase C Signalling In Skeletal Muscle: A Possible Link To Insulin Resistance," <i>Trans. Assoc. Am. Physicians</i> , 1991, 104:206-212;	
BC	12	CHIN, J. E., et al., "Overexpression of Protein Kinase C Isoenzymes α, βI, γ, and ε in Cells Overexpressing the Insulin Receptor," <i>J. Biol. Chem.</i> , 1993, 268: 6338-6347	
BC	13	COHEN P., "Dissection of the Protein Phosphorylation Cascades Involved in Insulin and Growth Factor Action," <i>Biochem. Soc. Trans.</i> , 1993, 21:555-567	
BC	14	COTTER D., et al. "Abnormalities of Wnt signalling in schizophrenia - evidence for neurodevelopmental abnormality," <i>Neuroreport</i> , 1998, 9:1379-1383;	
BC	15	CRAVEN, P. A. and Derubertis, F. R., "Protein Kinase C is Activated in Glomeruli from streptozotocin Diabetic Rats," <i>J. Clin. Invest.</i> , 1989, 83:1667-1675;	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

Application Number	10/008,982
Filing Date	12/06/2001
First Named Inventor	KUO, et al.
Group Art Unit	1614 12242
Examiner Name	COLEMAN
Attorney Docket Number	ORT-1500

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BC	16	CROSS, D. A. E., et al., "The Inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf", <i>Biochemical Journal</i> , 1994, 303:21-26	
BC	17	DANSO, D., et al., "The protein kinase C (PKC) inhibitor Ro32-0432 (Ro) significantly enhances mitomycin-C (MMC) induced apoptosis", <i>Proc. Am. Assoc. Cancer Res.</i> , 1997, 38:92	
BC	18	DEKKER, L. V., et al., "Protein Kinase C-β contributes to NADPH oxidase activation in neutrophils", <i>Biochem. J.</i> , 2000, 347:285-289	
BC	19	D'MELLO, S. R., et al., "Lithium induces Apoptosis in Immature Cerebellar Granule Cells but Promotes Survival of Mature Neurons", <i>Exp. Cell Res.</i> , 1994, 211:332-338	
BC	20	EASTMAN, Q., et al., "Regulation of LEF-1/TCF Transcription factors by Wnt and other signals," <i>Current Opinion in Cell Biology</i> , 1999, 11:233-240	
BC	21	ELDAR-FINKELMAN, H., et al., "Increased Glycogen Synthase Kinase-3 Activity in Diabetes-and Obesity-Prone C57BL/6J Mice", <i>Diabetes</i> , 1999, 48:1-5	
BC	22	ELDAR-FINKELMAN, H., et al., "Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells", <i>PNAS</i> , 1996, 93:10228-10233	
BC	23	ELDAR-FINKELMAN, H., and Krebs, E. G., "Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action", <i>PNAS</i> , 1997, 94:9660-9664	
BC	24	EMBI, N., et al., "Glycogen Synthase Kinase-3 from Rabbit Skeletal Muscle", <i>Eur. J. Biochem</i> , 1980, 107:519-527	
BC	25	FAUL, M. M., et al., "A General Approach to the Synthesis of Bisindolylmaleimides: Synthesis of Staurosporine Aglycone", <i>Synthesis</i> , 1995, 1511-1516	
BC	26	FAUL, M. M., et al., "Macrocyclic Bisindolylmaleimides: Synthesis by Inter-and Intramolecular Alkylation", <i>J. Org. Chem</i> , 1998, 63: 1961-1973	
BC	27	GAT, U., et al., "De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin," <i>Cell</i> , 1998, 95:605-614	
BC	28	GOULD, P. L., "Salt selection for basic drugs", <i>International J. Pharm.</i> , 1986, 33:201-217	
BC	29	GU, X., et al., "Increased Protein Kinase C and Isozyme Redistribution in Pressure-Overload Cardiac Hypertrophy in the Rat", <i>Circ. Res.</i> , 1994, 75:926-931	
BC	30	HANCOCK, B. C., et al., "Characteristics and significance of the Amorphous State in Pharmaceutical Systems", <i>Journal of Pharmaceutical Sciences</i> , 1997 86:1-12	
BC	31	HARA, H., et al., "Staurosporine, a Novel Protein Kinase C Inhibitor Prevents Postischemic Neuronal Damage in the Gerbil and Rat", <i>J. Cereb. Blood Flow Metab.</i> , 1990, 10:646-653	
BC	32	HARRINGTON, E.O., et al., "Enhancement of Migration by Protein Kinase Cα and Inhibition of Proliferation and Cell Cycle Progression by Protein Kinase Cδ in Capillary Endothelial Cells", <i>J. Biol. Chem.</i> , 1997, 272:7390-7397	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

MAY 24 2002
U.S. PATENT & TRADEMARK OFFICE
Substitute for form 1449A/PTOINFORMATION DISCLOSURE
STATEMENT BY APPLICANT(use as many sheets as necessary)
Sheet 4 of 8

Application Number	10/008,982
Filing Date	12/6/2001
First Named Inventor	KUO, et al
Group Art Unit	1814 1604
Examiner Name	COLEMAN
Attorney Docket Number	ORT-1551

RECEIVED
MAY 2002
U.S. PATENT & TRADEMARK OFFICE

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BC	33	HEGEMANN, L., et al., "Effects of tiflucarbine as a dual protein kinase C/calmodulin antagonist on proliferation of human keratinocytes and release of reactive oxygen species from human leukocytes", <i>Arch. Dermatol. Res.</i> , 1991, 283:456-460	
BC	34	HOEFLICH, K. P., et al., "Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation", <i>Nature</i> , 2000, 406:86-90	
BC	35	HONG, M., et al., "Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3", <i>J. Biol. Chem.</i> , 1997, 272:25326-32	
BC	36	HORN, F., et al., "Decreased Protein Kinase C Activity in Psoriatic Versus Normal Epidermis," <i>J. Invest. Dermatol.</i> , 1987, 88:220-222	
BC	37	HSIEH, J., et al., "Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function", <i>Proc. Natl. Acad. Sci. USA</i> , 1991, 88:9315-9319	
BC	38	HSIEH, J., et al., "Phosphorylation of the Human Vitamin D Receptor by Protein Kinase C", <i>J. Biol. Chem.</i> , 1993, 268:15118-15126	
BC	39	HUANG, K. P., "The mechanism of protein kinase C activation," <i>Trends Neurosci.</i> , 1989, 12:425-432	
BC	40	IKEDA, S., et al., "Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β-dependent phosphorylation of β-catenin," <i>EMBO J.</i> , 1998, 17:1371-1384	
BC	41	INOUGUCHI, T., et al., "Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation," <i>Proc. Natl. Acad. Sci. USA</i> , 1992, 89:11059-11065	
BC	42	ISHII, H., et al., "Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor", <i>Science</i> , 1996, 272:728-731	
BC	43	ISHII, H., et al., "Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus," <i>J. Mol. Med.</i> , 1998, 76:21-31	
BC	44	KARASIK, A., et al., "Increased Protein Kinase C Activity Is Linked to Reduced Insulin Receptor Autophosphorylation in Liver of Starved Rats," <i>J. Biol. Chem.</i> , 1990, 265:10226-10231	
BC	45	KELLY, T. A., et al., "Novel Non-Nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. 6. 2-Indol-3-yl-and 2-Azaindol-3-yl dipyridodiazepinones(1)," <i>J. Med. Chem.</i> 1997, 40: 2430-2433	
BC	46	KOBAYASHI, I., et al., "Platelet-activating factor modulates microvascular transport by stimulation of protein kinase C," <i>Amer. Phys. Soc.</i> , 1994, H1214-H1220	
BC	47	KONIG, A., et al., "The protein kinase C inhibitor RO 32-0432 enhances fludarabine-induced apoptosis in WSU-CLL chronic lymphocytic leukemia cells," <i>Blood</i> , 1997, 90, 10, Suppl. 1 Pt. 2).	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 8

Application Number	10/008,982
Filing Date	12/6/2001
First Named Inventor	KUO et al
Group Art Unit	1614 1634
Examiner Name	COLEMAN
Attorney Docket Number	ORT-1551

RECEIVED
MAY 28 2002
U.S. PATENT AND TRADEMARK OFFICE
1600 2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BC	48	LEE, T-S., et al., "Differential Regulation of Protein Kinase C and (Na,K)-Adenosine Triphosphatase Activities by Elevated Glucose Levels in Retinal Capillary Endothelial Cells," <i>J. Clin. Invest.</i> , 1989, 83:90-94	
BC	49	LEE, T-S., et al., "Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications," <i>Proc. Natl. Acad. Sci. USA</i> , 1989, 86:5141-5145	
BC	50	LEITGES, M., et al., "Immunodeficiency in Protein Kinase C β -Deficient Mice," <i>Science</i> , 1996, 273:788-789	
BC	51	LIJAM N., et al., "Social Interaction and Sensorimotor Gating Abnormalities in Mice Lacking Dvl1", <i>Cell</i> , 1997, 90:895-905	
BC	52	MAGEE, D. I AND BECK, E. J., "The use of the Ramberg-Backlund rearrangement for the formation of aza-macrocycles: a total synthesis of manzamine C," <i>Can. J. Chem.</i> , 2000, 78:1060-1066	
BC	53	MALMBERG, A. B., et al., "Preserved Acute Pain and Reduced Neuropathic Pain in Mice Lacking PKC γ ," <i>Science</i> 1997, 278:279-283	
BC	54	MANJI, H. K., et al., "Modulation of CNS Signal Transduction Pathways and Gene Expression by Mood-Stabilizing Agents: Therapeutic Implications," <i>J. Clin. Psychiatry</i> , 1999, 60:27-39 (suppl 2 for review)	
BC	55	MATSUMOTO, H. and SASAKI, Y., "Staurosporine, A Protein Kinase C Inhibitor Interferes With Proliferation of Arterial Smooth Muscle Cells," <i>Biochem. Biophys. Res. Commun.</i> , 1989, 158:105-109	
BC	56	MEYER, T., et al., "A Derivative of Staurosporine (CGP 41 251) Shows Selectivity For Protein Kinase C Inhibition and In Vitro Anti-Proliferative As Well As In Vivo Anti-Tumor Activity," <i>Int. J. Cancer</i> , 1989, 43:851-856	
BC	57	MILETIC, V., et al., "Loose ligation of the rat sciatic nerve is accompanied by changes in the subcellular content of protein kinase C beta II and gama in the spinal dorsal horn," <i>Neurosci. Lett.</i> , 2000, 288:199-202	
BC	58	MUID, R. E., et al., "A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli," <i>FEBS Lett.</i> , 1990, 293:169-172	
BC	59	MULQUEEN, M. J., et al., "Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor," <i>Agents Actions</i> , 1992, 37:85-89	
BC	60	MURRAY, N. R., et al., "Protein Kinase C Isotypes in Human Erythroleukemia (K562) Cell Proliferation and Differentiation," <i>J. Biol. Chem.</i> , 1993, 268: 15847-15853	
BC	61	NAGPALA, P.G., et al., "Protein Kinase C β (1) Overexpression Augments Phorbol Ester-Induced Increase in Endothelial Permeability," <i>J. Cell Physiol.</i> , 1996, 166:249-55	
BC	62	NECHUSHTAN, H., et al., "Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase C β ," <i>Blood</i> , 2000 (March), 95(5):1752-1757	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



MAY 26 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0033

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Application Number	10/008,982
Filing Date	12/6/2001
First Named Inventor	KUO et al
Group Art Unit	1614 1624
Examiner Name	COLEMAN
Attorney Docket Number	ORT-1551

RECEIVED
MAY 2002
TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BC	63	NONAKA, S. and CHUANG, D-M., "Neuroprotective effects of chronic lithium n focal cerebral ischemia in rats," NEUROREPORT, 1998, 9(9):2081-2084	
BC	64	PAP, M. and COOPER, G. M., "Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway," J. Biol. Chem., 1998, 273:19929-19932	
BC	65	PARKER P.J., et al., "Glycogen Synthase from Rabbit Skeletal Muscle; Effect of Insulin on the State of Phosphorylation of the Seven Phosphoserine Residues in vivo," Eur. J. Biochem., 1983, 130:227-234,	
BC	66	RABBI, M.F., et al., "The cAMP-Dependent Protein Kinase A and Protein Kinase C-β Pathways Synergistically Interact to Activate HIV-1 Transcription in Latently Infected Cells of Monocyte/Macrophage Lineage," Virology, 1998, 245(2):257-69	
BC	67	RAYNAUD, F. and EVAIN-BRION, D., "Protein kinase C activity in normal and psoriatic cells: cultures of fibroblasts and lymphocytes," Br. J. Dermatol., 1991, 124:542-546	
BC	68	REN, S., et al., "Protein kinase C-β mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells," Am. J. Physiol., 2000, 278:E656-E662	
BC	69	RO滕BERG, S. A., "Protein Kinase C in Neoplastic Cells" Biochemical and Molecular Aspects of Selected Cancers, 1991 1(2):25-73	
BC	70	SAUMA, S., et al., "Protein Kinase Cβ1 and Protein Kinase Cβ2 Activate p57 Mitogen-activated Protein Kinase and Block Differentiation in Colon Carcinoma Cells(1)," Cell Growth Differ., 1996, 7(5):587-94	
BC	71	SHIBATA, S., et al., "Neuroprotective effect of protein kinase C inhibitors on oxygen/glucose free-induced decreases I 2-deoxyglucose uptake and CA1 field potentials in rat hippocampal slices," Brain Res., 1992, 594:290-294	
BC	72	SHIMOHAMA, S., et al., "Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease," Neurology, 1993, 43:1407-1413	
BC	73	SLATER, M.J., et al., "Indolocarbazoles: Potent, Selective Inhibitors of Human Cytomegalovirus Replication," Biorg. & Med. Chem., 1999, 7:1067-1074	
BC	74	SONOKI, H., et al., "The role of protein kinase C in left ventricular relaxation impaired by global ischemia," Kokyu to Junkan, 1989 37:669-674 (English Abstract attached)	
BC	75	SRIVASTAVA A.K. and PANDEY S.K., "Potential mechanism (s) involved in the regulation of glycogen synthesis by insulin," Mol. and Cellular Biochem., 1998, 182:135-141	
BC	76	STRASSER, R. H., et al., "Selective Expression of Cardiac Protein Kinase C-Isoforms in Chronic Heart Failure and Myocardial Hypertrophy," Circulation, 1996, 94:I551	
BC	77	TEICHER, B.A., et al., "Antiangiogenic and Antitumor Effects of a Protein Kinase Cβ Inhibitor in Human T98G Glioblastoma Multiforme Xenografts," Clinical Cancer Research, 2001 7:634-640	
BC	78	TEICHER, B.A., et al., "Therapeutic potentiation by a protein kinase Cβ inhibitor (LY333531) along with radiation or chemotherapy," Proc. Am. Assoc. Cancer Res., 1998, 39(89 Meet.):384	
BC	79	TESFAMARIAM, B., et al., "Elevated Glucose Impairs Endothelium-dependent Relaxation by Activating Protein Kinase C," J. Clin. Invest., 1991, 87:1643-1648)	

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003
--------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-09)

Approved for use through 10/31/2002 OMB 0651-004
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Use a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 8

Application Number	10/008,982	111	2
Filing Date	12/6/2001	110	8
First Named Inventor	KUO et al	1601	2001
Group Art Unit	1614	1604	2002
Examiner Name	COLEMAN	1200	2000
Attorney Docket Number	ORT-1551	1000	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature	Brenda Coleman	Date Considered	Sept. 29, 2003
-----------------------	----------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Page 8 of 8

<i>Application Number</i>	10/008,982
<i>Filing Date</i>	December 6, 2001
<i>First Named Inventor</i>	G. Kuo et al.
<i>Group Art Unit</i>	1614 1624
<i>Examiner Name</i>	Not Assigned C0
<i>Attorney Docket Number</i>	ORT-1551

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

Brenda (Coleman)

Date Considered

Sept. 29, 2003